3696 — Insilico Medicine Cayman TopCo Cashflow Statement
0.000.00%
Last trade - 00:00- HK$32.77bn
- HK$31.15bn
- $56.24m
Annual cashflow statement for Insilico Medicine Cayman TopCo, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | |
| Standards: | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -222 | -212 | -17.1 | — |
| Depreciation | ||||
| Amortisation | ||||
| Non-Cash Items | 155 | 132 | -13.2 | — |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 17.6 | 45.2 | -33.1 | — |
| Change in Accounts Receivable | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Payable / Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -47.5 | -29.6 | -57.4 | — |
| Capital Expenditures | -11.2 | -2.97 | -0.925 | — |
| Purchase of Fixed Assets | ||||
| Purchase / Acquisition of Intangibles | ||||
| Other Investing Cash Flow Items | -2.36 | 3.66 | 8.35 | — |
| Acquisition of Business | ||||
| Sale of Business | ||||
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -13.6 | 0.69 | 7.42 | — |
| Financing Cash Flow Items | -1.83 | -0.788 | -0.384 | — |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 107 | -2.18 | -1.54 | — |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 46.3 | -30.7 | -51.2 | — |